RBB 004

Drug Profile

RBB 004

Alternative Names: RBB004

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rubicon Biotechnology
  • Class Anti-ischaemics; Ischaemic heart disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Cell death inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Myocardial infarction

Most Recent Events

  • 28 Jul 2017 Preclinical trials in Brain injuries in USA before July 2017 (Rubicon Biotechnology pipeline, July 2017)
  • 28 Jul 2017 Preclinical trials in Myocardial infarction in USA before July 2017 (Rubicon Biotechnology pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top